bioRxiv Science⌕ Search

Biology subjects

Best, G.

Publications and source records attributed to Best, G..

3 recordsLinked to original sources

Circadian clock control of translation fidelity through MetRS-mediated methionine misincorporation

Translation fidelity is generally viewed as a constitutive process that deteriorates under stress and aging. Here we show that the fidelity of amino acid incorporation is instead dynamically regulated by the circadian clock. In Neurospora crassa, methionine (Met) misincorporation into proteins exhibits robust daily rhythms, peaking at night coincident with elevated reactive oxygen species (ROS). Rhythmic Met misincorporation requires the circadian clock, the ERK-family MAPK MAK1, and MAK1-dependent phosphorylation of methionyl-tRNA synthetase (MetRS), linking circadian signaling to regulated mistranslation associated with oxidative stress resistance. Preventing MetRS phosphorylation abolishes rhythmic Met misincorporation, impairs growth, and increases sensitivity to oxidative stress, whereas a phosphomimetic MetRS mutant enhances oxidative stress survival. Proteome-wide analyses identified thousands of Met misincorporation events, including a rhythmic subset that oscillates independently of corresponding protein abundance, suggesting that mistranslation dynamically remodels proteome composition across the day. Together, these findings establish translation fidelity as a regulated circadian output and support a model in which the circadian clock temporally regulates mistranslation to enhance oxidative stress resilience. Significance StatementBiological clocks regulate translation termination fidelity, but whether they also control the accuracy of amino acid incorporation during protein synthesis was unknown. We show that the circadian clock drives rhythmic methionine misincorporation into proteins through ERK-family MAPK signaling and phosphorylation of methionyl-tRNA synthetase. Methionine misincorporation peaks during periods of elevated oxidative stress, and disrupting this regulation compromises oxidative stress survival, whereas constitutive activation enhances resistance. Together with previous work on translation termination fidelity, these findings reveal that biological clocks regulate multiple layers of translation fidelity and identify adaptive mistranslation as a mechanism that promotes cellular resilience.

molecular biology↗

A novel in-vitro model of the bone marrow microenvironment in AML identifies CD44 and Focal Adhesion Kinase as therapeutic targets to reverse cell adhesion-mediated drug resistance

Acute myeloid leukemia (AML) is an aggressive neoplasm. Although most patients respond to induction therapy, they commonly relapse due to recurrent disease in the bone marrow microenvironment (BMME). So, disruption of the BMME, releasing tumour cells into the peripheral circulation, has therapeutic potential. Using both primary donor AML cells and cell lines, we developed an in-vitro co-culture model of the AML BMME. We used this model to identify the most effective agent(s) to block AML cell adherence and reverse adhesion-mediated treatment resistanc E. We identified anti-CD44 treatment significantly increased the efficacy of cytarabine. However, some AML cells remained adhered, and transcriptional analysis identified focal adhesion kinase (FAK) signalling as a contributing factor; adhered cells showed elevated FAK phosphorylation that was reduced by the FAK inhibitor, defactinib. Importantly, we demonstrated that anti-CD44 and defactinib were highly synergistic at diminishing adhesion of the most primitive CD34high AML cells in primary autologous co-cultures. Taken together, we identified anti-CD44 and defactinib as a promising therapeutic combination to release AML cells from the chemoprotective AML BMME. As anti-CD44 is already available as a recombinant humanised monoclonal antibody, the combination of this agent with defactinib could be rapidly tested in AML clinical trials.

cancer biology↗

The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.

Despite advances in treatment, a significant proportion of patients with chronic lymphocytic leukaemia (CLL) will relapse with drug-resistant disease. Recent studies demonstrate that the imipridones ONC-201 and ONC-212 and the more potent TR-compounds are effective against a range of different cancers, including acute myeloid leukaemia and tumours of the brain, breast, and prostate. These drugs induce cell death through inhibition of mitochondrial function and activation of the mitochondrial protease, caseinolytic protease (CIpP), and the unfolded protein response (UPR). Here we demonstrate that a drug in this class, TR-57, has efficacy as a single agent and is synergistic with venetoclax against CLL cells cultured under in vitro conditions that mimic the tumour microenvironment. The inhibitory effects of TR-57 on cell survival, proliferation and migration were irrespective of poor-risk features, including aberrations of TP53. Changes in protein expression suggest the mechanisms of action of TR-57 and its synergy with venetoclax involve activation of the UPR, inhibition of the AKT and ERK1/2 pathways and a pro-apoptotic shift in expression of proteins of the BCL-2 family. The study suggests TR-57, as a single agent and in combination with venetoclax, may represent an effective treatment option for CLL, including for patients with poor-risk disease.

cancer biology↗